Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: Non-alcoholic liver disease and alcoholic liver disease begin as simple steatosis that may progress to steatohepatitis and ensuing liver-related complications such as cirrhosis and hepatocellular carcinoma (HCC). We explored differences in characteristics between non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitisrelated (ASH) HCC. Methods: NASH and ASH patients were identified from our department’s prospective HCC database. A total of 54 and 45 patients met predefined inclusion and exclusion criteria for the NASH-HCC and ASH-HCC groups, respectively. Clinical, biochemical and tumor characteristics were studied. Results: NASH-HCC patients were older compared to ASH-HCC patients (72±9 vs. 66±9 years, P<0.001) and less male predominant (65% vs. 98%, P<0.001). Prevalence of diabetes mellitus (78% vs. 36%, P<0.001) and hypertension (80% vs. 58%, P<0.001) were significantly higher in the NASH-HCC group. Liver function tests and Child-Pugh scores were similar. There were no differences in alpha-fetoprotein level, lesions found at diagnosis (unifocal/multifocal) or prevalence of portal vein invasion. In both groups, almost half of the patients were in TNM stage 4 at the time of diagnosis and more than 50% of patients were not suitable for any therapy. Median survival in the NASH-HCC and ASH-HCC groups were 13 and 7 months respectively (P=0.113). Conclusions: Despite significant differences in demography of the NASH-HCC and ASH-HCC groups, liver and tumor characteristics were comparable. Most patients were diagnosed late and were not amenable to curative or locoregional therapies. Better characterization of patients with NASH and ASH at risk of HCC is necessary to optimize screening, surveillance, and management strategies.
Abstract
Background/Aims: Non-alcoholic liver disease and alcoholic liver disease begin as simple steatosis that may progress to steatohepatitis and ensuing liver-related complications such as cirrhosis and hepatocellular carcinoma (HCC). We explored differences in characteristics between non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitisrelated (ASH) HCC. Methods: NASH and ASH patients were identified from our department’s prospective HCC database. A total of 54 and 45 patients met predefined inclusion and exclusion criteria for the NASH-HCC and ASH-HCC groups, respectively. Clinical, biochemical and tumor characteristics were studied. Results: NASH-HCC patients were older compared to ASH-HCC patients (72±9 vs. 66±9 years, P<0.001) and less male predominant (65% vs. 98%, P<0.001). Prevalence of diabetes mellitus (78% vs. 36%, P<0.001) and hypertension (80% vs. 58%, P<0.001) were significantly higher in the NASH-HCC group. Liver function tests and Child-Pugh scores were similar. There were no differences in alpha-fetoprotein level, lesions found at diagnosis (unifocal/multifocal) or prevalence of portal vein invasion. In both groups, almost half of the patients were in TNM stage 4 at the time of diagnosis and more than 50% of patients were not suitable for any therapy. Median survival in the NASH-HCC and ASH-HCC groups were 13 and 7 months respectively (P=0.113). Conclusions: Despite significant differences in demography of the NASH-HCC and ASH-HCC groups, liver and tumor characteristics were comparable. Most patients were diagnosed late and were not amenable to curative or locoregional therapies. Better characterization of patients with NASH and ASH at risk of HCC is necessary to optimize screening, surveillance, and management strategies.
참고문헌 (50)
- El-Serag HB, "Hepatocellular carcinoma : epidemiology and molecular carcinogenesis", Gastroenterology, 132, pp.2537~2576 (2007)
- Goh GB, "Changing epidemiology of Hepatocellular carcinoma in Asia", Best Pract Res Clin Gastroenterol, 29, pp.919~928 (2015)
- Bosch FX, "Epidemiology of hepatocellular carcinoma", Clin Liver Dis, 9, pp.191~211 (2005)
- Cadwell SH, "NASH and cryptogenic cirrhosis : a histological analysis", Ann Hepatol, 8, pp.346~352 (2009)
- Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
- Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
- Albhaisi S, "Recent advances in understanding and managing non-alcoholic fatty liver disease", F1000Res, 7(F1000 Faculty Rev), pp.720~ (2018)
- Tannapfel A, "Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease", Virchows Arch, 458, pp.511~523 (2011)
- Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
- Ekstedt M, "Long-term follow-up of patients with NAFLD and elevated liver enzymes", Hepatology, 44, pp.865~873 (2006)
- Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with the nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397.e10 (2015)
- Askgaard G, "Alcohol drinking pattern and risk of alcoholic liver cirrhosis : a prospective cohort study", J Hepatol, 62, pp.1061~1067 (2015)
- Åberg F, "Binge drinking and the risk of liver events : a population-based cohort study", Liver Int, 37, pp.1373~1381 (2017)
- Singal AK, "ACG clinical guideline : alcoholic liver disease", Am J Gastroenterol, 113, pp.175~194 (2018)
- Donato F, "Alcohol and hepatocellular carcinoma : the effect of lifetime intake and hepatitis virus infections in men and women", Am J Epidemiol, 155, pp.323~331 (2002)
- Bagnardi V, "Alcohol consumption and the risk of cancer : a meta-analysis", Alcohol Res Health, 25, pp.263~270 (2001)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Alberti KGMM, "Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation", Diabet Med, 23, pp.469~480 (2006)
- Wong VW, "Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-Part 1 : definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2017)
- Younossi ZM, "Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to 2009", Hepatology, 62, pp.1723~1730 (2015)
- Lee SS, "Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma", BMC Cancer, 13, pp.335~ (2013)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of alcohol-related liver disease", J Hepatol, 69, pp.154~181 (2018)
- Colli A, "Severe liver fibrosis or cirrhosis : accuracy of US for detection--analysis of 300 cases", Radiology, 227, pp.89~94 (2003)
- Kudo M, "Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study", Intervirology, 51(Suppl 1), pp.17~26 (2008)
- Yeom SK, "Prediction of liver cirrhosis, using diagnostic imaging tools", World J Hepatol, 7, pp.2069~2079 (2015)
- Chitturi S, "NASH and insulin resistance : insulin hypersecretion and specific association with the insulin resistance syndrome", Hepatology, 35, pp.373~379 (2002)
- Bugianesi E, "Expanding the natural history of nonalcoholic steatohepatitis : from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
- Scaglioni F, "ASH and NASH", Dig Dis, 29, pp.202~210 (2011)
- Brunt EM, "Histopathology of non-alcoholic fatty liver disease", Clin Liver Dis, 13, pp.533~544 (2009)
- Zhang DY, "Fibrosis-dependent mechanisms of hepatocarcinogenesis", Hepatology, 56, pp.769~775 (2012)
- Sidharthan S, "Mechanisms of alcohol-induced hepatocellular carcinoma", Hepatol Int, 8, pp.452~457 (2013)
- Stickel F, "Cocarcinogenic effects of alcohol in hepatocarcinogenesis", Gut, 51, pp.132~139 (2002)
- Michelotti GA, "NAFLD, NASH and liver cancer", Nat Rev Gastroenterol Hepatol, 10, pp.656~665 (2013)
- Caldwell SH, "Cryptogenic cirrhosis : clinical characterization and risk factors for underlying disease", Hepatology, 29, pp.664~669 (1999)
- Starley BQ, "Nonalcoholic fatty liver disease and hepatocellular carcinoma : a weighty connection", Hepatology, 51, pp.1820~1832 (2010)
- Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
- Shimizu I, "Trends in alcoholic liver disease research: clinical and scientific aspects", pp.23~40 (2012), InTech
- Wilsnack RW, "Gender and alcohol consumption : pattern from the multinational GENACIS project", Addiction, 104, pp.1487~1500 (2009)
- French DJ, "Gender differences in alcohol consumption among middle-aged and older adults in Australia, the United States and Korea", Aust N Z J Public Health, 38, pp.332~339 (2014)
- Tokushige K, "Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology : report of the nationwide survey", J Gastroenterol, 46, pp.1230~1237 (2011)
- Yasui K, "Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma", Clin Gastroenterol Hepatol, 9, pp.428~433 (2011)
- Stine JG, "Systemic review with meta-analysis : risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases", Aliment Pharmacol Ther, 48, pp.696~703 (2018)
- Mittal S, "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.124~131.e1 (2016)
- Seitz HK, "Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress", Biol Chem, 387, pp.349~360 (2006)
- Bralet MP, "Hepatocellular carcinoma occurring in nonfibrotic liver : epidemiologic and histopathologic analysis of 80 French cases", Hepatology, 32, pp.200~204 (2000)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Kanwal F, "Risk of hepatocellular cancer in patient with non-alcoholic fatty liver disease", Gastroenterology, 155, pp.1828~1837.e2 (2018)
- Flemming JA, "Risk prediction of hepatocellular carcinoma in patients with cirrhosis : the ADRESS-HCC risk model", Cancer, 120, pp.3485~3493 (2014)
- Weinmann A, "Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma", BMC Cancer, 15, pp.210~ (2015)
- Costentin CE, "Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients : results of a prospective, nationwide study", Cancer, 124, pp.1964~1972 (2018)